Paul Watkins
Paul Watkins
Professor of Pharmacy, Medicine and Public Health University of North Carolina, Chapel Hill
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl, J Zhang, Y Lin, J Lamba, M Assem, J Schuetz, PB Watkins, ...
Nature genetics 27 (4), 383-391, 2001
Case definition and phenotype standardization in drug‐induced liver injury
GP Aithal, PB Watkins, RJ Andrade, D Larrey, M Molokhia, H Takikawa, ...
Clinical Pharmacology & Therapeutics 89 (6), 806-815, 2011
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States
N Chalasani, RJ Fontana, HL Bonkovsky, PB Watkins, T Davern, ...
Gastroenterology 135 (6), 1924-1934. e4, 2008
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug–drug interaction
WC Lau, LA Waskell, PB Watkins, CJ Neer, K Horowitz, AS Hopp, AR Tait, ...
Circulation 107 (1), 32-37, 2003
Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease
PB Watkins, HJ Zimmerman, MJ Knapp, SI Gracon, KW Lewis
Jama 271 (13), 992-998, 1994
Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
KS Lown, RR Mayo, AB Leichtman, H Hsiao, DK Turgeon, ...
Clinical pharmacology & therapeutics 62 (3), 248-260, 1997
Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.
KS Lown, DG Bailey, RJ Fontana, SK Janardan, CH Adair, LA Fortlage, ...
The Journal of clinical investigation 99 (10), 2545-2553, 1997
Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study
N Chalasani, HL Bonkovsky, R Fontana, W Lee, A Stolz, J Talwalkar, ...
Gastroenterology 148 (7), 1340-1352. e7, 2015
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial
PB Watkins, N Kaplowitz, JT Slattery, CR Colonese, SV Colucci, ...
Jama 296 (1), 87-93, 2006
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance
WC Lau, PA Gurbel, PB Watkins, CJ Neer, AS Hopp, DGM Carville, ...
Circulation 109 (2), 166-171, 2004
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.
JC Kolars, P Schmiedlin-Ren, JD Schuetz, C Fang, PB Watkins
The Journal of clinical investigation 90 (5), 1871-1878, 1992
Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man.
PB Watkins, SA Wrighton, EG Schuetz, DT Molowa, PS Guzelian
The Journal of clinical investigation 80 (4), 1029-1036, 1987
Hepatic dysfunction associated with troglitazone
PB Watkins, RW Whitcomb
New England Journal of Medicine 338 (13), 916-917, 1998
Liver transplantation for acute liver failure from drug induced liver injury in the United States
MW Russo, JA Galanko, R Shrestha, MW Fried, P Watkins
Liver Transplantation 10 (8), 1018-1023, 2004
Drug-induced liver injury
RJ Andrade, N Chalasani, ES Björnsson, A Suzuki, GA Kullak-Ublick, ...
Nature Reviews Disease Primers 5 (1), 58, 2019
Incidence and etiology of drug-induced liver injury in mainland China
T Shen, Y Liu, J Shang, Q Xie, J Li, M Yan, J Xu, J Niu, J Liu, PB Watkins, ...
Gastroenterology 156 (8), 2230-2241. e11, 2019
First-pass metabolism of cyclosporin by the gut
JC Kolars, PB Watkins, RM Merion, WM Awni
The Lancet 338 (8781), 1488-1490, 1991
The barrier function of CYP3A4 and P-glycoprotein in the small bowel
PB Watkins
Advanced drug delivery reviews 27 (2-3), 161-170, 1997
CYP3A gene expression in human gut epithelium
JC Kolars, KS Lown, P Schmiedlin-Ren, M Ghosh, C Fang, SA Wrighton, ...
Pharmacogenetics and Genomics 4 (5), 247-259, 1994
Noninvasive tests of CYP3A enzymes
PB Watkins
Pharmacogenetics and Genomics 4 (4), 171-184, 1994
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20